NASDAQ:WVE - Wave Life Sciences Stock Price, Price Target & More

Wave Life Sciences trades on the NASDAQ under the ticker symbol "WVE."

Wave Life Sciences Ltd (NASDAQ:WVE) issued its earnings results on Wednesday, May, 9th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.90) by $0.36. The firm earned $1.42 million during the quarter, compared to analyst estimates of $6.59 million. Wave Life Sciences had a negative return on equity of 76.93% and a negative net margin of 2,613.03%. View Wave Life Sciences' Earnings History.

Wave Life Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Wave Life Sciences.

4 brokers have issued twelve-month price targets for Wave Life Sciences' shares. Their predictions range from $40.00 to $65.00. On average, they expect Wave Life Sciences' stock price to reach $56.75 in the next twelve months. This suggests a possible upside of 53.0% from the stock's current price. View Analyst Ratings for Wave Life Sciences.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Wave Life Sciences in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Wave Life Sciences include Madrigal Pharmaceuticals (MDGL), GW Pharmaceuticals (GWPH), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE), Array Biopharma (ARRY), OPKO Health (OPK), Ironwood Pharmaceuticals (IRWD), Amicus Therapeutics (FOLD), The Medicines (MDCO), Blueprint Medicines (BPMC), Ascendis Pharma A/S (ASND), Intercept Pharmaceuticals (ICPT), Horizon Pharma (HZNP), Heron Therapeutics (HRTX) and Emergent Biosolutions (EBS).

Media stories about WVE stock have been trending positive recently, Accern Sentiment reports. The research group ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Wave Life Sciences earned a news impact score of 0.28 on Accern's scale. They also assigned news stories about the company an impact score of 45.15 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Shares of WVE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of WVE stock can currently be purchased for approximately $37.10.

Wave Life Sciences has a market capitalization of $1.08 billion and generates $3.70 million in revenue each year. The company earns $-102,030,000.00 in net income (profit) each year or ($3.85) on an earnings per share basis. Wave Life Sciences employs 168 workers across the globe.

Wave Life Sciences' mailing address is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. The company can be reached via phone at 65-6236-3388 or via email at [email protected]